Join us in the latest episode where pharmacist and head of a regional physicians association, Matthias Flume, engages in a thought-provoking discussion with host Stefan Walzer, exploring the intricate tapestry of reforms enveloped within the AMNOG (Arzneimittelmarktneuordnungsgesetz) 2.0, especially scrutinizing those unveiled in 2023!

🚀 Dive Deep into the Core of Pharmaceutical Reforms!

Matthias unearths various pivotal changes, including the mandated discounts for products with no additional benefit rating and the perceptible adjustments in the orphan drug area, dissecting the threshold reduction for annual sales in the full regular benefit assessment. 🚀

🌎 Explore the Global Impact!

Navigate through their insightful discussion on how these reforms potentially sculpt Germany’s presence on the global stage, especially in the orphan drugs market, and assess Germany's unique positioning in evaluating them! 🌎

💡 Illuminating the Opaqueness of Drug Pricing!

Embark on a journey through the complexities and pragmatic implications of drug pricing, dissecting the nuances of arbitration boards, pricing mechanisms, and the often intricate physician prescription behaviors amidst the recent reforms. 💡

🤔 Facing the Challenges Head-On!

Explore the potential disconnect between pricing strategies and actual prescription practices, as our experts shed light on the vital need for enhancing transparency and communication with physicians regarding pricing negotiations and adjustments. 🤔

👥 Join Matthias and Stefan as they scrutinize the germane issues of drug pricing, contemplate future adjustments within the system, and ponder upon the possible shifts influenced by the upcoming national elections and continual changes within the healthcare landscape! 👥

🎧 Tune in to immerse yourself in a conversation that not only explores the multidimensional aspects of the healthcare and pharmaceutical reimbursement system but also poses potent questions regarding its future amidst regulatory and structural shifts! 🎧

A journey through the dynamics of pharmaceutical pricing and reforms awaits you, amplifying both economic and patient care perspectives amidst the shifting tides of the healthcare system in Germany! Don’t miss it! 🚀🚀

Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

Switzerland is seen as a small but still attractive market for pharmaceuticals, even though that the Swiss decision-makers are considered as tough and sometimes even difficult. A core issue might especially be, that the assessment and negotiations primarily happen intransparently „behind the doors“. 

Dr. Heiner Sandmeier has been part of the drug evaluation committee advising the Swiss decision makers for over a century and opens his insights and secrets to all listeners. 

Some of the topics Dr. Sandmeier and reimbursement veteran Dr. Stefan Walzer discuss are as follows: 

• What are the main drivers for a positive decision in Switzerland?
• Who is involved in the decision process?
• What are the challenges as well as possible solutions for the main issues?
• What are the differences to other countries in Europe?

And last but not least: Why should you still consider to enter the Swiss market with an innovative pharmaceutical product?

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccess podcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #pricingstrategy #negotiations #pricing #pharmaceuticals #switzerland #innovation #reimbursement

Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

We are living in an age of massive medical innovation including a lot of new modalities especially in the area of ATMPs, but also beyond. Within this area, but obviously also beyond, there are core questions in the area of tensions such as the followings:

- What are the differences between Clinical Development and Medical Affairs?

- When should a company start telling their medical story about a new product?

- What are the differences between drugs and vaccinations from a medical affairs’ perspective?

- And how should market access and medical affairs ideally work together?

Market access veteran Dr. Stefan Walzer and Dr. Mike Rosenblatt, one of the pioneers in Medical Affairs, Commercialisation and Market Access continued their come together in Boston in May 2023 in this epic podcast episode. 

Don’t miss this amazing conversation. 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #medicalaffairs #pricingstrategy #negotiations

#pricing #medtech #pharmaceuticals #usa #innovation #vaccination 

🎧 Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi  

🇨🇭Switzerland has one of the highest healthcare spendings per person across the world! At the same time, one could also say that Switzerland has also one of the best healthcare systems... 

💥 … but health care expert Dr. Peter Intra calls it still a developing country in terms of digitalisation! In this MAP podcast episode, health care system veteran Dr. Stefan Walzer and Dr. Peter Indra are discussing the current state of digital health in Switzerland, possible improvements and the inspiring example of Estonia.

What are we talking about, when we address the topic of digitalisation and e-health?

1. Data + AI, which is dealing with the data
2. Infrastructure like electronic patient record and vaccination registries
3. Processes 

Don't miss this inspiring conversation with spill-overs for all countries around the world. 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #digitization #digitalhealth #funding #ehealth #healthcare #digitalisation #healthservices #switzerland

Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

Companies, including start-ups, are usually focused solely on the development of the product and/or the technical platform in the early days. As understandable and important these aspects are, if they don’t start to think about their public communications strategy from the very beginning, they might be in danger of failing.                                                           

Already in the very early stages of the development of pharmaceuticals or med tech products, companies need to think about the following key points: 

Will patients need and want the new product?

Will physicians prescribe it?

Will payers pay for it?

And thus they should come up with a convincing value story towards all stakeholders as only if they could convince all of these, investors will see the potential return of investment! But ultimately, all of that needs to be communicated… The reimbursement veteran Dr. Stefan Walzer these and more aspects around (global and local) communication with the communication expert Dr. Arne Näveke. 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #medtech #pharmaceuticals #communications #funding #medicaldevices #germany

Listen to this podcast on your favourite podcast player: https://lnkd.in/eGemZRTi

New methods such as diagnostics need to be assessed and the included in the reimbursement catalogue in the outpatient setting in Germany. However, key question remains which requirements are needed for such an evaluation and who is responsible for it. In some instances the responsible body is a sub-committee of the German federal Committee (G-BA) the so-called evaluation committee. But how does that body come to a conclusion and what do they really assess. How does price setting work in such an environment.

The reimbursement veteran Dr. Stefan Walzer discussed all of these questions and many more secrets with the Head of the arbitration board of the before-mentioned evaluation committee, Prof. Jürgen Wasem.

✏️ Take the chance to stay connected and subscribe with your favourite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

#pricing #medtech #diagnostics #arbitrationboard #funding #medicaldevices #germany

Even though there are great accelerators and a lot of innovative product ideas, only very few products actually make it to the market and are commercially successful. What is the reason behind that and even more important how could this situation be improved?

In this podcast episode, Dr. Stefan Walzer and Dr. Kasia Hein-Peters are discussing the necessity for an overarching business and company strategy approach. In health care this is sometimes referred to a lifecycle approach, the invented approach by Dr. Kasia Hein-Peters is called DIVE. Within these approaches, all stakeholders would always need to be captured and dealt with - clinical development, regulatory and payers.

✏️ Take the chance to stay connected and subscribe with your favourite podcast platform: https://lnkd.in/dyTZ3yQb

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #innovation #pricing #drugs #medtech #livescience #strategy

In order to commercialize a health care product in the USA, the US FDA would need to approve it. But what is the standard process and how early would a company need to be involved and maybe even get advice? Additionally, the core question remains how could US FDA requirements be aligned with potential payer needs - are there any relationships?

The #marketaccess veterans Dr. Stefan Walzer and Dr. Jamie Cross are discussing the principles as well as some very specific details. 

✏️ Take the chance to stay connected and subscribe with your favorite podcast platform: https://lnkd.in/dyTZ3yQb

MAP is the first and only bi-weekly #marketaccesspodcast provided by MArS. For more information about MArS Market Access & Pricing Strategy GmbH visit: https://lnkd.in/db8aQWf

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

#pricing #drugs #medtech #usa #fda

The Inflation Reduction Act in the US will change fundamental how the US pharmaceutical industry works. 

The IRA will negotiate their own prices for Medicare and Medicaid, which will have the result, that they will not pay the same prices in the future anymore.

With Medicare the government directly funds pharmaceuticals for 65+ years old population.

With Medicaid the government fund low income and other vulnerable populations.

Given, that the private insurance sector will follow the lead of government negotiated prices, all prices will decrease.

Revenues in the US will decline, and it will be interesting to see, what that will mean economically and in terms of availability of pharmaceuticals for the US and the global market?

Please enjoy the discussion of market access veterans Dr. Stefan Walzer and Anita Burell MBA on this major change in the major market for pharmaceuticals.

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations

#pricing #drugs #medtech #usa #inflationreductionact #inflation #ira

The market access experts Dr. Stefan Walzer and Heather Wellam are discussing the market access process in Japan, one of the largest health care markets in the world!

In Japan not all products need to go through the full process, so an important question is, what the criteria are and what role does cost-effectiveness play in this market? What are the differences in the process between drugs and medical devices?

On top, the two experts are also discussing the opportunity to apply for price premiums in the reimbursement process. 

Take the chance to stay connected and subscribe with your favorite podcasting platform or directly listen on our website: https://lnkd.in/dZtyKw8B

MAP is the first and only bi-weekly market access podcast provided by MArS. For more information about MArS Market Access and Pricing Strategy visit: marketaccess-pricingstrategy.de

#podcasthost #podcastshow #podcastepisode #marketaccess #marketaccesspodcast #reimbursement #pricingstrategy #negotiations #pricing #drugs #medtech #japan